NB-9402
Asset
Covalent irreversible allosteric small-molecule SARM1 inhibitor preventing axonal degeneration
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- NAD+ metabolism
- 0
- Indications
- 0
- Trials
- 1
- Developer
Indications
1No named disease
Phase 1, nurabio.com, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.